Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / TAK - Biogen's Alzheimer's Drug And Other News: The Good Bad And Ugly Of Biopharma


TAK - Biogen's Alzheimer's Drug And Other News: The Good Bad And Ugly Of Biopharma

Biogen receives priority review for Alzheimer’s drug candidate

Biogen (BIIB) announced that the FDA has accepted its Biologics License Application for aducanumab. The application has been granted Priority Review and its PDUFA date has been set at March 7, 2021. The agency has stated that it may take earlier action than the date. The company is collaborating with Eisai Co. Ltd. of Japan for developing this investigational treatment for Alzheimer’s disease.

Aducanumab has the potential to become the first treatment to bring significant change in the course of the disease for patients. The

Read more ...

Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...